Results showed that replacing a half-hour of sedentary time with a half-hour of moderate-to-vigorous physical activity every ...

The FDA also gave full approval to the Novavax COVID vaccine (Nuvaxovid) using this approach, approving it for those ages 65 ...

NEW YORK (Reuters) -The U.S. Food and Drug Administration plans to require new clinical trials for approval of annual ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

The agency will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to ...

WASHINGTON (AP) — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by ...

In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years of age and older and high-risk individuals aged 12-64 years.

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

With lung cancer rates among non-smokers rising, especially young East Asian women, a new study released Monday is touting ...